TrialCrossover Trial of AD036 in Obstructive Sleep Apnea
Trial details
- Registry ID
- NCT04445688
- Phase
- Phase 2
APMD
Apnimed
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
8Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Crossover Trial of AD036 in Obstructive Sleep ApneaNCT04445688 | Apnimed | Phase 2 | Completed | 2020-12-01Actual |
| Trial of AD113 and Atomoxetine in OSA Patients With HypertensionNCT04905979 | Apnimed | Phase 2 | Completed | 2023-01-31Actual |
| Parallel Arm Trial of AD109 and AD504 In Patients With OSANCT05071612 | Apnimed | Phase 2 | Completed | 2022-07-20Actual |
| AD816 Crossover StudyNCT05793684 | Apnimed | Phase 2 | Completed | 2023-11-09Actual |
| Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)NCT05811247 | Apnimed | Phase 3 | Completed | 2025-05-07Actual |
| Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)NCT05813275 | Apnimed | Phase 3 | Completed | 2025-03-10Actual |
| Study That Tests AD109 in Patients Taking GLP-1 DrugsNCT06400615 | Apnimed | Phase 2 | Completed | 2024-12-26Actual |
| Continuation Protocol for Obstructive Sleep Apnea (OSA)NCT06566820 | Apnimed | Phase 3 | Enrolling by invitation | 2026-06-30Estimated |
Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
Trial details
- Registry ID
- NCT04905979
- Phase
- Phase 2
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
Trial details
- Registry ID
- NCT05071612
- Phase
- Phase 2
AD816 Crossover Study
Trial details
- Registry ID
- NCT05793684
- Phase
- Phase 2
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
Trial details
- Registry ID
- NCT05811247
- Phase
- Phase 3
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
Trial details
- Registry ID
- NCT05813275
- Phase
- Phase 3
Study That Tests AD109 in Patients Taking GLP-1 Drugs
Trial details
- Registry ID
- NCT06400615
- Phase
- Phase 2
Continuation Protocol for Obstructive Sleep Apnea (OSA)
Trial details
- Registry ID
- NCT06566820
- Phase
- Phase 3
Latest recorded trial changes
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275 · Apnimed
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Change from Baseline in Apnea-Hypopnea Index (AHI)
+ Updated value
measure: Change From Baseline in Apnea-Hypopnea Index (AHI)
The saved outcome text may be shortened. Check the source for full wording.
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
NCT05071612 · Apnimed
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Change in AHI, Combined AD109 Dose Arms vs. Combined Placebo Arms
+ Updated value
measure: Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo
The saved outcome text may be shortened. Check the source for full wording.
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
NCT05071612 · Apnimed
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Change in AHI, combined AD109 dose arms vs. combined placebo arms
+ Updated value
measure: Change in AHI, Combined AD109 Dose Arms vs. Combined Placebo Arms
The saved outcome text may be shortened. Check the source for full wording.
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
NCT05811247 · Apnimed
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Efficacy of AD109 on airway obstruction in mild to severe OSA
+ Updated value
measure: Change from Baseline in Apnea-Hypopnea Index (AHI)
The saved outcome text may be shortened. Check the source for full wording.
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275 · Apnimed
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Efficacy of AD109 on airway obstruction in mild to sever OSA
+ Updated value
measure: Change from Baseline in Apnea-Hypopnea Index (AHI)
The saved outcome text may be shortened. Check the source for full wording.